Fetal gender and aneuploidy detection using fetal cells in maternal blood: Analysis of NIFTY I data

D. W. Bianchi, J. L. Simpson, L. G. Jackson, S. Elias, W. Holzgreve, M. I. Evans, K. A. Dukes, L. M. Sullivan, K. W. Klinger, F. Z. Bischoff, S. Hahn, K. L. Johnson, Dorothy E. Lewis, R. J. Wapner, F. De La Cruz

Research output: Contribution to journalArticlepeer-review

287 Scopus citations


Objectives: The National Institute of Child Health and Human Development Fetal Cell Isolation Study (NIFTY) is a prospective, multicenter clinical project to develop non-invasive methods of prenatal diagnosis. The initial objective was to assess the utility of fetal cells in the peripheral blood of pregnant women to diagnose or screen for fetal chromosome abnormalities. Methods: Results of fluorescence in situ hybridization (FISH) analysis on interphase nuclei of fetal cells recovered from maternal blood were compared to metaphase karyotypes of fetal cells obtained by amniocentesis or chorionic villus sampling (CVS). After the first 5 years of the study we performed a planned analysis of the data. We report here the data from 2744 fully processed pre-procedural blood samples; 1292 samples were from women carrying singleton male fetuses. Results: Target cell recovery and fetal cell detection were better using magnetic-based separation systems (MACS) than with flow-sorting (FACS). Blinded FISH assessment of samples from women carrying singleton male fetuses found at least one cell with an X and Y signal in 41.4% of cases (95% CI: 37.4%, 45.5%). The false-positive rate of gender detection was 11.1% (95% CI: 6.1,16.1%). This was higher than expected due to the use of indirectly labeled FISH probes in one center. The detection rate of finding at least one aneuploid cell in cases of fetal aneuploidy was 74.4% (95% CI: 76.0%, 99.0%), with a false-positive rate estimated to be between 0.6% and 4.1%. Conclusions. The sensitivity of aneuploidy detection using fetal cell analysis from maternal blood is comparable to single marker prenatal serum screening, but technological advances are needed before fetal cell analysis has clinical application as part of a multiple marker method for non-invasive prenatal screening. The limitations of the present study, i.e. multiple processing protocols, are being addressed in the ongoing study.

Original languageEnglish (US)
Pages (from-to)609-615
Number of pages7
JournalPrenatal Diagnosis
Issue number7
StatePublished - 2002


  • FISH
  • Fetal cells in maternal blood
  • Non-invasive
  • Prenatal diagnosis

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Genetics(clinical)


Dive into the research topics of 'Fetal gender and aneuploidy detection using fetal cells in maternal blood: Analysis of NIFTY I data'. Together they form a unique fingerprint.

Cite this